Introduction {#s1}
============

Heart failure is a major cause of morbidity and mortality in a large part of the developed world and the global prevalence has been estimated to 37.7 million people ([@B31]). The disease is often defined as the clinical syndrome that is manifested when the heart muscle is unable to pump enough blood to meet the body's needs for oxygen ([@B25]). As an attempt to compensate for this impaired heart capacity, the body acts *via* a number of different mechanisms which include enlarging of the heart, increased heart output and narrowing of blood vessels. However, as these measures only are temporary, the patients starts to experience symptoms such as fatigue and breathing problems as the diseases is progressing ([@B31]).

Calcium and magnesium are two minerals that are involved in several physiological processes of the cardiovascular system ([@B10]; [@B20]). Excessive calcium intake has been found to induce hypercalcemia which in turn may result in vascular calcification and thus increased risk of cardiovascular disease ([@B22]). On the other hand, magnesium has been suggested to promote vasodilatation partially in a direct manner by acting as a calcium antagonist in smooth muscle cells but also indirectly *via* modulation of endothelial cell function ([@B10]). Available evidence indicates that high serum calcium and low serum magnesium concentrations increase the risk of coronary artery disease ([@B2]; [@B5]; [@B21]; [@B13]; [@B14]), a major risk factor for heart failure ([@B31]). Yet, few studies has attempted to investigate the associations between these minerals and incidence of heart failure. For calcium, past research shows tendencies towards increased risk of disease ([@B17]). However, findings are not consistent ([@B27]; [@B6]). On the other hand and in line with findings for coronary artery disease, an inverse relationship has been suggested for blood levels and dietary intake of magnesium and heart failure incidence ([@B29]; [@B17]; [@B11]; [@B26]; [@B28]). However, due to the limited data available and the fact that most studies, with one exception ([@B6]), were observational, it is uncertain whether the associations are causal and not biased by reverse causality or residual confounding.

In the present study, we applied a two-sample Mendelian randomization design using summary estimates to assess whether serum calcium and magnesium concentrations are causally associated with heart failure. Mendelian randomization is a method that utilizes genetic variants, often in terms of single nucleotide polymorphisms (SNPs), associated with the exposure of interest to estimate the effect on disease outcomes. Due to the random distribution of alleles during gametogenesis, MR has the possibility of evading some of the methodological limitations of other epidemiological study designs, including confounding and reverse causation bias.

Methods {#s2}
=======

SNP Identification and Data Sources {#s2_1}
-----------------------------------

Information on SNPs associated with serum calcium and magnesium concentrations was collected from two meta-analyses of discovery and replication genome-wide association studies (GWASs) of these minerals in European-descent individuals ([@B18]; [@B19]). In those GWASs, seven and six SNPs reached genome-wide significance (*p* \< 5 × 10^−8^) for serum calcium (among 61,079 participants) and serum magnesium (among 23,829 participants), respectively, and were selected as instrumental variables. The selected SNPs were independent (i.e. not in linkage disequilibrium, r^2^ \< 0.001) and explained 0.9% of the variance of calcium concentrations and 1.6% of the variance of magnesium concentrations. Summary statistics data were extracted for each SNP ([**Table 1**](#T1){ref-type="table"}).

###### 

Characteristics of the single-nucleotide polymorphisms associated with serum calcium and magnesium concentrations and their associations with heart failure.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mineral     SNP            Chr   Nearby\           EA   EAF    F-stat   Association with serum\   Association with heart failure                              
                                   gene                                   calcium or magnesium                                                                  
  ----------- -------------- ----- ----------------- ---- ------ -------- ------------------------- -------------------------------- --------- -------- ------- -------
  Calcium     rs1801725      3     *CASR*            T    0.15   299      0.071                     0.004                            8.9E−86   −0.032   0.027   0.236

  Calcium     rs1570669      20    *CYP24A1*         G    0.34   37       0.018                     0.003                            9.1E−12   0.014    0.018   0.457

  Calcium     rs1550532      2     *DGKD*            C    0.31   37       0.018                     0.003                            8.2E−11   0.004    0.018   0.829

  Calcium     rs7481584      11    *CARS*            G    0.70   37       0.018                     0.003                            1.2E−10   0.003    0.018   0.888

  Calcium     rs780094       2     *GCKR*            T    0.42   37       0.017                     0.003                            1.3E−10   0.008    0.017   0.652

  Calcium     rs7336933      13    *DGKH/KIAA0564*   G    0.85   31       0.022                     0.004                            9.1E−10   −0.013   0.024   0.594

  Calcium     rs10491003     10    *GATA3*           T    0.09   31       0.027                     0.005                            4.8E−09   −0.030   0.031   0.344

  Magnesium   rs4072037      1     *MUC1*            T    0.53   136      0.010                     0.001                            2.1E−36   0.006    0.017   0.744

  Magnesium   rs7965584^‡^   12    *ATP2B1*          A    0.71   60       0.007                     0.001                            1.1E−16   −0.021   0.020   0.286

  Magnesium   rs3925584      11    *DCDC5*           T    0.55   60       0.006                     0.001                            5.2E−16   0.009    0.017   0.607

  Magnesium   rs11144134     9     *TRPM6*           C    0.08   55       0.011                     0.001                            8.2E−15   −0.022   0.032   0.505

  Magnesium   rs13146355     4     *SHROOM3*         A    0.44   45       0.005                     0.001                            6.3E−13   −0.052   0.018   0.003

  Magnesium   rs448378       3     *MDS1*            A    0.53   31       0.004                     0.001                            1.3E−08   0.003    0.017   0.864
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chr, chromosome; EA, effect allele (i.e., the allele associated with higher calcium or magnesium concentrations; F-stat, F-statistic; SE, standard error.

\*β coefficient of the calcium- or magnesium-increasing allele on serum concentrations of calcium (in mg/dl) and magnesium (in mmol/L).

^†^β coefficient of the mineral-increasing allele on the log odds ratio of heart failure.

^‡^A proxy SNP (rs10858938) associated with the specified SNP (pairwise r^2^ = 0.95) was used in the heart failure dataset. The effect allele for the proxy SNP is G.

Following SNP identification, publicly available summary statistics data on SNP--heart failure associations were obtained from a discovery GWAS on heart failure in the UK Biobank study ([@B1]) and accessed through the Broad Institute Cardiovascular Disease Knowledge Portal (<http://broadcvdi.org>). In the UK Biobank study, all-cause heart failure was defined as either self-reported heart failure/pulmonary edema or cardiomyopathy or an international classification of disease code indicative of heart/ventricular failure or a cardiomyopathy of any cause ([@B1]). Individuals with left ventricular dysfunction and without coronary artery disease was defined as having non-ischemic cardiomyopathy ([@B1]). The heart failure dataset included summary statistics data based on 394,156 participants (6,504 all-cause heart failure cases and 387,652 non-cases) of European ancestry. The analyses of the underlying studies included in the GWASs of calcium, magnesium, and heart failure were adjusted for age, sex and, if needed, study-specific covariates (e.g., principal components of ancestry and study center). There was no overlap between individuals included in the GWASs on the minerals and those included in the GWAS on heart failure.

Assessment of Pleiotropy {#s2_2}
------------------------

We searched the human genotype-phenotype association database PhenoScanner V2 ([@B9]) for pleiotropic associations of the instrumental variables with potential confounders. The following SNPs were identified as pleiotropic with potential confounders: rs780094 near *GCKR* which is associated with the metabolic syndrome and its components (blood lipids, fasting glucose and insulin concentrations, and type 2 diabetes); rs3925584 near *DCDC5* and rs13146355 near *SHROOM3* which are associated with kidney function; and rs448378 near *MDS1* which is associated with blood pressure. The association with blood pressure was considered to represent vertical (mediated) pleiotropy because magnesium supplementation has been shown to reduce blood pressure in randomized controlled trials ([@B30]). The other associations may represent horizontal pleiotropy and the corresponding SNPs were excluded in sensitivity analyses.

Statistical Analysis {#s2_3}
--------------------

The primary analyses of causal associations of instrument variables for serum calcium and magnesium with all-cause heart failure were performed using the standard inverse variance weighted method ([@B4]). By using this method, the causal effect of an exposure on an outcome is estimated as the ratio (Wald estimate) of the SNP-outcome association and the SNP-exposure association. The inverse weighted variance method provides a reliable estimate of the causal effect of the exposure on the disease outcome if the following assumptions are valid for the instrument variables: 1) the SNPs are robustly associated with the exposure of interest 2) the SNPs are not associated with any potential confounders of the exposure-outcome relationship and 3) the SNP only affects the outcome through the exposure and not *via* any other causal pathway ([**Figure 1**](#f1){ref-type="fig"}) ([@B23]; [@B7]). Secondly, we performed sensitivity analyses using the weighted median ([@B4]), weighted mode-based estimate ([@B8]) and MR-Egger methods ([@B4]). The weighted median method provides a reliable effect estimate when at least 50% of the weight in the analysis comes from valid instrumental variables. The MR-Egger method is used for detection of and adjustment for directional pleiotropy. In a secondary analysis, we used the inverse-variance weighted method to analyze the associations between genetically predicted serum calcium and magnesium concentrations and nonischemic cardiomyopathy. All odds ratios (OR) were scaled to reflect a one standard deviation (SD) increment of serum calcium and magnesium concentrations (0.5 mg/dl and 0.1 mmol/dl for calcium and magnesium, respectively). The SD corresponded to the rounded mean SD of serum concentrations of calcium and magnesium in the cohorts included in the GWASs of these minerals ([@B18]; [@B19]). The statistical analysis was carried out using Stata (StataCorp, College Station, TX) and the mrrboust package ([@B24]). All tests were two sided and the level of significance was set to a Bonferroni-corrected threshold of *p \<*0.01 (correcting for two exposures and two outcomes). Statistical power was estimated by using the method by Brion et al. ([@B3]). We had 80% power to detect an OR of 1.37 (or 0.63) for serum calcium and 0.72 (or 1.28) for serum magnesium concentrations. However, because the number of heart failure cases was relatively small, we also used 97 SNPs associated with body mass index (BMI) ([@B16]) as a positive control and made post-hoc power analyses to assess the statistical power of the present study.

![Graphical representation of the key assumptions underlying the Mendelian Randomization study design. SNP; Single nucleotide polymorphism.](fgene-10-01069-g001){#f1}

Results {#s3}
=======

The associations of genetically predicted serum calcium and magnesium concentrations with all-cause heart failure based on the inverse variance weighted method are presented in [**Figures 2**](#f2){ref-type="fig"}--[**4**](#f4){ref-type="fig"}. None of the calcium-related SNPs nor the overall estimate, combining all SNPs, were associated with heart failure (OR 0.89 95% CI 0.67--1.17; *p* = 0.41), and there was no heterogeneity among SNPs (*p* = 0.83). Of the six magnesium-related SNPs, rs12146355 near *SHROOM3* was associated with heart failure (*p* = 0.003). However, the association with heart failure across all six SNPs did not reach statistical significance (OR 0.89 95% CI 0.72--1.10; *p* = 0.28) but there was suggestive evidence of heterogeneity among SNPs (*p* = 0.09). After exclusion of the SNP in *SHROOM3*, the OR was 0.98 (95% CI 0.78--1.22) and there was no heterogeneity between SNPs (*p* = 0.73). The null associations of serum calcium and magnesium concentrations with heart failure remained after exclusion of SNPs associated with the metabolic syndrome and its components (rs780094) and kidney function (rs3925584 and rs13146355). The null associations also remained when using the weighted median method; the ORs were 0.87 (95% CI 0.62--1.22) for calcium and 0.98 (95% CI 0.75--1.29) for magnesium. In analysis using the weighted mode-based estimate, the ORs were 0.81 (95% CI 0.57--1.16) for calcium and 1.05 (95% CI 0.78--1.41) for magnesium. The MR-Egger regression analysis did not reveal any signs of directional pleiotropy for calcium (intercept 0.017; 95% CI −0.012 to 0.046; *p* = 0.24) or magnesium (intercept −0.023; 95% CI −0.088 to 0.043; *p* = 0.50). Moreover, genetically predicted serum calcium and magnesium concentrations were not associated with non-ischemic cardiomyopathy (n = 1816 cases); the ORs were 1.02 (95% CI 0.61--1.69; *p* = 0.48) for calcium and 0.80 (95% CI 0.53--1.19; *p* = 0.67) for magnesium. As a positive control, we used BMI, which was statistically significantly positively associated with heart failure. The OR was 1.53 (95% CI 1.32--1.77; *p* = 2.1 × 10^−8^) per one SD increase in genetically predicted BMI. The post-hoc power analyses suggested that we had about 13% and 20% power to detect an OR of 0.89 for calcium and magnesium, respectively.

![Associations of genetically predicted one standard deviation increase of serum calcium and magnesium concentrations with heart failure. One standard deviation corresponds to 0.5 mg/dl and 0.1 mmol/dl for calcium and magnesium, respectively. Overall refers to the overall estimate generated by the inverse variance weighted method, combining all SNPs. CI, confidence interval; OR, odds ratio; SD, standard deviation; SNP, single-nucleotide polymorphism. \*A proxy SNP (rs10858938) associated with the specified SNP (pairwise r^2^ = 0.95) was used in the heart failure dataset.](fgene-10-01069-g002){#f2}

![Scatter plot of the summary statistics estimates for calcium and heart failure. The solid line represents the inverse-variance weighted estimate. SNP, single-nucleotide polymorphism; HF, heart failure; Ca, Calcium.](fgene-10-01069-g003){#f3}

![Scatter plot of the summary statistics estimates for magnesium and heart failure. The solid line represents the inverse-variance weighted estimate. SNP, single-nucleotide polymorphism; HF, heart failure, Mg, magnesium.](fgene-10-01069-g004){#f4}

Discussion {#s4}
==========

The overall results of this MR study did not find any evidence for a causal association between minerals and heart failure and thus do not support findings from previous observational studies, suggesting a positive association between serum calcium and heart failure risk ([@B17]) as well as an inverse association between serum magnesium and heart failure risk ([@B29]; [@B17]; [@B11]; [@B26]; [@B28]). However, given that previous studies are scarce and findings are limited by potential residual confounding and reverse causality, caution must be applied when interpreting these data. On the other hand, and in line with our results, heart failure was neither associated with baseline blood calcium in an observational study ([@B27]), nor affected by calcium supplementation in a randomized controlled trial ([@B6]).

Of the six loci associated with magnesium, *SHROOM3* was statistically significantly inversely associated with heart failure. The SNP in this locus is associated with decreased glomerular filtration rate and therefore may increase serum magnesium concentrations *via* decreased renal filtration and excretion of the ion. However, as there was no consistent association with any of the other five SNPs with heart failure, it is not likely that there is a causal association between serum magnesium concentrations and heart failure.

The major strength of this study is the MR design, which reduces the risk of bias from confounding factors and reverse causality. The most important limitation is the low statistical power resulting from the relatively small number of heart failure cases in the outcome data set and the small proportion of variance in serum calcium and magnesium concentrations explained by the instruments. Together, it is possible that these factors might have hampered the detection of a potential relationship between minerals and heart failure. On the other hand, the number of heart failure cases was sufficient to detect a statistically significant association between the positive control, BMI, and heart failure. Moreover, previous studies of the MR design using the same instruments have demonstrated statistically significant positive and inverse associations of serum concentrations of calcium and magnesium, respectively, with other cardiovascular diseases ([@B13]; [@B14]; Larsson et al., 2019a; Larsson et al., 2019b). However, the post-hoc power analysis suggested that we only had ∼20% power to detect an OR of 0.89 for magnesium and 13% power to detect an OR of 0.89 for calcium. Thus, we cannot rule out that there may be an effect of low magnitude for calcium and magnesium on heart failure which this study was unable to detect. Thus, we call for cautious interpretation of these findings.

Another issue that has to be addressed in MR studies is pleiotropy, which can be either vertical or horizontal. Vertical pleiotropy occurs if genetic variants associates with other traits downstream the main trait and thus mediates the effect of the former. This type of pleiotropy does not violate the MR assumptions and does not bias the MR effect estimates. Horizontal pleiotropy occurs if SNPs have an effect on the outcome through another trait or pathway than the one under investigation. If the horizonal pleiotropy is directional, all traits have similar effects on the outcome and will lead to an exaggerated MR estimate. If horizonal pleiotropy is balanced, the different traits will have dissimilar effects on the outcome and the association will instead be biased towards the null. In this study, we assessed occurrence of direction horizontal pleiotropy by applying MR-Egger regression. The results of the analysis did not reveal any signs of pleiotropic effects. However, this method has low power, especially when the number of SNPs are limited. For this reason, we also performed a PhenoScanner search through which we identified four SNPs that had pleiotropic associations with potential confounders or intermediates. However, the null associations of serum calcium and magnesium concentrations with heart failure remained after exclusion of those SNPs. A final limitation of our study is that we did not have access to individual-level data and therefore could not examine potential non-linear associations of serum calcium and magnesium concentrations with heart failure risk.

Conclusions {#s5}
===========

The present study based on the MR design did not find any evidence for a causal association between minerals and heart failure. Thus we were unable to confirm the positive and inverse association of serum calcium and magnesium, respectively, with heart failure risk that have been observed in previous observational studies. Given the scarcity of studies addressing the research question and the inconclusive findings, further research on the possible causal role of calcium and magnesium for heart failure are needed.
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